The initiation of coverage by Barclays with an Equal-Weight rating suggests a neutral outlook on Humana's stock. The price target of $356 indicates Barclays' expectation of where the stock price might head, but the Equal-Weight rating does not suggest a strong bullish or bearish stance. Therefore, the short-term impact on Humana's stock price is likely to be moderate, as investors may view this as a validation of the current price level rather than a signal to buy or sell aggressively.